Loading...

Athenex

DB:2MT
Snowflake Description

High growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2MT
DB
$741M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. The last earnings update was 39 days ago. More info.


Add to Portfolio Compare Print
2MT Share Price and Events
7 Day Returns
-7.7%
DB:2MT
-1.4%
DE Biotechs
2.4%
DE Market
1 Year Returns
-28.1%
DB:2MT
-10.6%
DE Biotechs
-6.2%
DE Market
2MT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Athenex (2MT) -7.7% -8.2% -7.5% -28.1% - -
DE Biotechs -1.4% 2.6% -7.7% -10.6% 54.2% 8%
DE Market 2.4% 3% 7.4% -6.2% 9.6% 14.1%
1 Year Return vs Industry and Market
  • 2MT underperformed the Biotechs industry which returned -10.6% over the past year.
  • 2MT underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

2MT Value

 Is Athenex undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Athenex. This is due to cash flow or dividend data being unavailable. The share price is €9.67.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Athenex's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Athenex's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:2MT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.82
NasdaqGS:ATNX Share Price ** NasdaqGS (2019-04-18) in USD $11.06
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.41x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Athenex.

DB:2MT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ATNX Share Price ÷ EPS (both in USD)

= 11.06 ÷ -1.82

-6.08x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Athenex is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Athenex is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Athenex's expected growth come at a high price?
Raw Data
DB:2MT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.08x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
52.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Athenex, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Athenex's assets?
Raw Data
DB:2MT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $2.08
NasdaqGS:ATNX Share Price * NasdaqGS (2019-04-18) in USD $11.06
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:2MT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ATNX Share Price ÷ Book Value per Share (both in USD)

= 11.06 ÷ 2.08

5.32x

* Primary Listing of Athenex.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Athenex is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Athenex's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Athenex has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

2MT Future Performance

 How is Athenex expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
52.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Athenex expected to grow at an attractive rate?
  • Athenex's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Athenex's earnings growth is expected to exceed the Germany market average.
  • Athenex's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:2MT Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:2MT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 52.9%
DB:2MT Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts 32.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:2MT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:2MT Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 470 -50 298 4
2022-12-31 329 -78 141 4
2021-12-31 239 -86 -49 5
2020-12-31 133 -99 -109 8
2019-12-31 96 -119 -128 8
DB:2MT Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 89 -109 -117
2018-09-30 83 -93 -119
2018-06-30 78 -71 -96
2018-03-31 71 -73 -97
2017-12-31 38 -82 -131
2017-09-30 28 -76 -143
2017-06-30 20 -77 -144
2017-03-31 21 -61 -118
2016-12-31 21 -48 -88
2016-09-30 21 -43 -61

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Athenex's earnings are expected to grow significantly at over 20% yearly.
  • Athenex's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:2MT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from Athenex Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2MT Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 2.71 8.57 -0.61 4.00
2022-12-31 1.29 5.23 -0.98 4.00
2021-12-31 -0.02 2.30 -1.07 5.00
2020-12-31 -1.50 -0.68 -2.36 7.00
2019-12-31 -1.91 -1.45 -2.53 8.00
DB:2MT Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.82
2018-09-30 -1.90
2018-06-30 -1.59
2018-03-31 -1.77
2017-12-31 -2.63
2017-09-30 -3.11
2017-06-30 -3.47
2017-03-31 -2.91
2016-12-31 -2.19
2016-09-30 -1.56

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Athenex will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Athenex's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Athenex has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

2MT Past Performance

  How has Athenex performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Athenex's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Athenex does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Athenex's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Athenex's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Athenex's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Athenex Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2MT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 89.10 -117.44 49.01
2018-09-30 82.70 -118.61 49.71
2018-06-30 78.27 -95.71 48.58
2018-03-31 71.30 -97.48 49.39
2017-12-31 38.04 -131.17 46.11
2017-09-30 28.28 -142.94 44.01
2017-06-30 19.91 -144.29 40.28
2017-03-31 20.50 -118.09 31.27
2016-12-31 20.55 -87.72 25.96
2016-09-30 20.51 -61.31 20.76
2015-12-31 13.94 -50.60 25.75
2014-12-31 1.21 -17.73 5.35 1.90

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Athenex has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Athenex has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Athenex improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Athenex's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Athenex has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

2MT Health

 How is Athenex's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Athenex's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Athenex is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Athenex's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Athenex's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Athenex Company Filings, last reported 3 months ago.

DB:2MT Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 128.77 46.76 107.42
2018-09-30 152.06 46.53 141.42
2018-06-30 124.41 1.50 80.66
2018-03-31 156.09 1.66 106.48
2017-12-31 90.72 1.98 51.04
2017-09-30 114.90 1.80 69.04
2017-06-30 120.37 8.76 85.30
2017-03-31 -3.62 45.82 29.09
2016-12-31 34.67 33.01 41.75
2016-09-30 69.61 30.09 55.37
2015-12-31 98.04 3.65 55.77
2014-12-31 27.84 0.00 27.99
  • Athenex's level of debt (36.3%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Athenex's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Athenex has less than a year of cash runway based on current free cash flow.
  • Athenex has less than a year of cash runway if free cash flow continues to grow at historical rates of 29.6% each year.
X
Financial health checks
We assess Athenex's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Athenex has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

2MT Dividends

 What is Athenex's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Athenex dividends. Estimated to be 0% next year.
If you bought €2,000 of Athenex shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Athenex's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Athenex's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:2MT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:2MT Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Athenex has not reported any payouts.
  • Unable to verify if Athenex's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Athenex's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Athenex has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Athenex's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Athenex's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Athenex afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Athenex has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

2MT Management

 What is the CEO of Athenex's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Johnson Lau
COMPENSATION $4,922,430
AGE 58
TENURE AS CEO 8.3 years
CEO Bio

Dr. Yiu-Nam Lau, also known as Johnson, MBBS, MD, FRCP, Ph.D., has been the Chief Executive Officer of Athenex, Inc. since 2011. Dr. Lau is the Vice Chairman and CEO of Axis Therapeutics. Dr. Lau serves as a Senior Advisor of Novartis. He is serving on the Board of Porton Fine Chemicals, and private companies including Avalon, Avagenex Limited, Aiviva Corporation, and Hong Kong X-tech Startup platform as a general partner and mentor. Dr. Lau has had extensive leadership experience in both scientific and business management. Dr. Lau served as Managing Director of Healthcare Investment Banking of Roth Capital Partners. He served as the Chairman and Chief Executive Officer of Valeant Pharmaceuticals International. He served as Chief Executive Officer and President of Ribapharm Inc. from April 17, 2002 to January 22, 2003 and served as its Chairman from November 2002 to January 22, 2003 and served as its Independent Contractor from January 2003 to December 2003. Dr. Lau has a wealth of experience from the medical, pharmaceutical and corporate fields, having a distinguished background in both academic medicine and executive-level management of pharmaceutical and biotechnology companies. He served as a Senior Vice President of ICN Pharmaceuticals from March 2000 until the completion of this offering and Head of Research and Development, where he played a role in raising $525 million through the sale of convertible bonds that facilitated the restructuring of that company, as well as establishing a number of strategic partnerships on their behalf. He served as a Senior Director of Antiviral Therapy at Schering-Plough Research Institute from 1997 to February 2000. Dr. Lau has been an Executive Chairman of Athenex, Inc. since December 2003. He serves as a Director of Comprehensive Drug Enterprises Limited. He serves as Independent Non-Executive Director of C-MER Eye Care Holdings Ltd since October 19, 2017. He serves as a Director of XenoBiotic Laboratories. He served as a Member of Business Advisory Board of Life Science Institute, LLC. He served as a Director of Celsus Therapeutics Plc since April 25, 2007. Dr. Lau served as an Independent Director of Chelsea Therapeutics International, Ltd. (formerly Ivory Capital Corp.) and its subsidiary Chelsea Therapeutics Inc. from September 2004 to July 2012. He served as a Director of Ribapharm Inc. from April 17, 2002 to January 22, 2003 and Vioquest Pharmaceuticals Inc. since November 2005. Dr. Lau has a distinguished background in both academic medicine and executive-level management of pharmaceutical and biotechnology companies. He served as a faculty member at the University of Florida from 1992 to 1996. From 1989 to 1991, he served as a Faculty Member at the Institute of Liver Studies, King's College Hospital School of Medicine and Dentistry, University of London. He is also an Executive Board Member of the charity Project Vision and is an honorary professor/adjunct professor of the University of Hong Kong, Hong Kong Polytechnic University and Chongqing Southwestern Hospital, and a member of the Advisory Board of the School of Biomedical Sciences of the Chinese University of Hong Kong. He played a significant role in the FDA approval of Ribavirin/Interferon and Pegylated Interferon alpha-2b. He has published over 200 scientific papers, more than 40 reviews/editorials in leading scientific journals and edited two books. He is a Fellow of the Royal College of Physicians of United Kingdom. Dr. Lau holds an M.B.B.S. and M.D. from the University of Hong Kong and the degrees of M.R.C.P. and F.R.C.P. from the Royal College of Physicians.

CEO Compensation
  • Johnson's compensation has increased whilst company is loss making.
  • Johnson's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Athenex management team in years:

2.2
Average Tenure
65
Average Age
  • The tenure for the Athenex management team is about average.
Management Team

Johnson Lau

TITLE
Chairman & CEO
COMPENSATION
$5M
AGE
58
TENURE
8.3 yrs

Jeffrey Yordon

TITLE
COO & President of Athenex Pharmaceutical Division
COMPENSATION
$2M
AGE
69
TENURE
2.2 yrs

Rudolf Kwan

TITLE
Executive VP & Chief Medical Officer
COMPENSATION
$1M
AGE
65
TENURE
5.3 yrs

Antony Leung

TITLE
Strategic & Business Advisor
COMPENSATION
$123K
AGE
66
TENURE
1.1 yrs

Allen Barnett

TITLE
Co-Founder & President Emeritus
TENURE
8.3 yrs

Randoll Sze

TITLE
Chief Financial Officer
TENURE
0.7 yrs

Li Shen

TITLE
VP of Financial Reporting
AGE
50
TENURE
1.3 yrs

Teresa Bair

TITLE
Senior Vice President of Administration & Legal Affairs
TENURE
0.3 yrs

Jacqueline Li

TITLE
Director of Corporate Development & Investor Relations

Mary Hughes

TITLE
Director of Human Resources
TENURE
3.7 yrs
Board of Directors Tenure

Average tenure and age of the Athenex board of directors in years:

2.5
Average Tenure
65.5
Average Age
  • The average tenure for the Athenex board of directors is less than 3 years, this suggests a new board.
Board of Directors

Johnson Lau

TITLE
Chairman & CEO
COMPENSATION
$5M
AGE
58
TENURE
15.4 yrs

Kim Campbell

TITLE
Lead Independent Director
COMPENSATION
$228K
AGE
71
TENURE
2.3 yrs

Benson Tsang

TITLE
Director
AGE
53
TENURE
0.8 yrs

Stephanie Davis

TITLE
Director
TENURE
0.1 yrs

Jinn Wu

TITLE
Independent Director
COMPENSATION
$216K
AGE
69
TENURE
12 yrs

Dan Von Hoff

TITLE
Member of Clinical Scientific Advisory Board
AGE
70
TENURE
2.6 yrs

Manson Fok

TITLE
Director
COMPENSATION
$205K
AGE
61
TENURE
3.8 yrs

John Vierling

TITLE
Director
AGE
72
TENURE
0.1 yrs

Jordan Kanfer

TITLE
Director

John Koh

TITLE
Director
AGE
62
Who owns this company?
Recent Insider Trading
  • Athenex insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
28. Mar 19 Buy Yiu-Nam Lau Individual 28. Mar 19 28. Mar 19 10,000 €11.05 €110,484
27. Mar 19 Buy Yiu-Nam Lau Individual 27. Mar 19 27. Mar 19 10,000 €11.02 €110,199
26. Mar 19 Buy Wei Zuo Individual 25. Mar 19 25. Mar 19 1,000 €11.02 €11,022
25. Mar 19 Buy Yiu-Nam Lau Individual 25. Mar 19 25. Mar 19 10,000 €11.00 €110,046
21. Mar 19 Buy Yiu-Nam Lau Individual 21. Mar 19 21. Mar 19 1,000 €11.08 €11,079
20. Mar 19 Buy Yiu-Nam Lau Individual 20. Mar 19 20. Mar 19 10,500 €10.57 €110,968
19. Mar 19 Buy Yiu-Nam Lau Individual 19. Mar 19 19. Mar 19 18,649 €10.69 €199,293
18. Mar 19 Buy Yiu-Nam Lau Individual 18. Mar 19 18. Mar 19 4,000 €11.05 €44,181
18. Mar 19 Sell Sheldon Trainor-Degirolamo Individual 14. Mar 19 15. Mar 19 -54,085 €10.41 €-562,228
15. Mar 19 Buy Yiu-Nam Lau Individual 15. Mar 19 15. Mar 19 12,000 €10.40 €124,743
14. Mar 19 Sell Sheldon Trainor-Degirolamo Individual 13. Mar 19 13. Mar 19 -45,915 €10.41 €-478,055
14. Mar 19 Sell Songyi Zhang Individual 11. Mar 19 13. Mar 19 -120,053 €10.52 €-1,261,290
12. Mar 19 Buy Yiu-Nam Lau Individual 12. Mar 19 12. Mar 19 2,814 €10.45 €29,416
11. Mar 19 Buy Yiu-Nam Lau Individual 11. Mar 19 11. Mar 19 10,000 €10.49 €104,889
03. Dec 18 Sell Songyi Zhang Individual 29. Nov 18 30. Nov 18 -1,000,000 €11.68 €-11,615,846
19. Nov 18 Buy Yiu-Nam Lau Individual 19. Nov 18 19. Nov 18 10,000 €10.26 €102,589
19. Nov 18 Buy Rudolf Kwan Individual 19. Nov 18 19. Nov 18 1,000 €10.21 €10,213
15. Nov 18 Buy Rudolf Kwan Individual 14. Nov 18 14. Nov 18 5,000 €9.14 €45,724
14. Nov 18 Buy Yiu-Nam Lau Individual 14. Nov 18 14. Nov 18 40,000 €9.25 €370,052
14. Nov 18 Buy Rudolf Kwan Individual 14. Nov 18 14. Nov 18 10,000 €9.27 €92,690
14. Nov 18 Buy Jinn Wu Individual 14. Nov 18 14. Nov 18 10,000 €9.06 €90,569
14. Nov 18 Buy Simon Pedder Individual 14. Nov 18 14. Nov 18 2,908 €9.06 €26,358
14. Nov 18 Buy Jeffrey Yordon Individual 14. Nov 18 14. Nov 18 9,500 €9.27 €88,055
14. Nov 18 Buy Randoll Sze Individual 14. Nov 18 14. Nov 18 1,000 €9.06 €9,061
15. Oct 18 Buy Jinn Wu Individual 15. Oct 18 15. Oct 18 12,500 €11.62 €145,274
27. Sep 18 Buy Yiu-Nam Lau Individual 27. Sep 18 27. Sep 18 2,000 €13.42 €26,835
07. Sep 18 Buy Jinn Wu Individual 06. Sep 18 06. Sep 18 2,500 €13.85 €34,621
07. Sep 18 Buy Yiu-Nam Lau Individual 06. Sep 18 06. Sep 18 5,000 €13.64 €68,175
30. Aug 18 Sell Songyi Zhang Individual 28. Aug 18 29. Aug 18 -51,029 €14.49 €-724,624
28. Aug 18 Sell Songyi Zhang Individual 24. Aug 18 27. Aug 18 -53,439 €14.71 €-783,299
27. Aug 18 Sell Songyi Zhang Individual 23. Aug 18 23. Aug 18 -25,748 €14.93 €-384,416
23. Aug 18 Sell Songyi Zhang Individual 21. Aug 18 22. Aug 18 -102,734 €14.99 €-1,527,560
21. Aug 18 Sell Songyi Zhang Individual 17. Aug 18 20. Aug 18 -116,133 €15.02 €-1,741,757
21. Aug 18 Buy Jinn Wu Individual 20. Aug 18 20. Aug 18 5,000 €15.04 €75,198
21. Aug 18 Sell Songyi Zhang Individual 14. Aug 18 16. Aug 18 -147,165 €15.65 €-2,194,459
07. Jun 18 Sell Sheldon Trainor-Degirolamo Individual 06. Jun 18 06. Jun 18 -12,401 €14.29 €-177,150
06. Jun 18 Sell Sheldon Trainor-Degirolamo Individual 05. Jun 18 05. Jun 18 -57,421 €14.40 €-827,033
05. Jun 18 Sell Sheldon Trainor-Degirolamo Individual 04. Jun 18 04. Jun 18 -31,633 €14.38 €-454,913
01. Jun 18 Sell Songyi Zhang Individual 29. May 18 30. May 18 -100,000 €13.85 €-1,382,389
30. May 18 Sell Sheldon Trainor-Degirolamo Individual 24. May 18 24. May 18 -8,858 €14.40 €-127,528
29. May 18 Sell Songyi Zhang Individual 24. May 18 25. May 18 -9,592 €14.38 €-136,687
24. May 18 Sell Sheldon Trainor-Degirolamo Individual 15. May 18 23. May 18 -121,688 €14.55 €-1,768,618
23. May 18 Sell Songyi Zhang Individual 15. May 18 17. May 18 -100,000 €14.35 €-1,430,425
X
Management checks
We assess Athenex's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Athenex has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

2MT News

Simply Wall St News

2MT Company Info

Description

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company’s Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and oral eribulin, an intravenous anticancer drug to treat certain patients with breast cancer and advanced liposarcoma. In addition, the company offers Src Kinase product candidates comprising KX2-391 ointments for actinic keratosis, skin cancers, and psoriasis; KX-01 oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and Pegtomarginase, an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was founded in 2003 and is headquartered in Buffalo, New York.

Details
Name: Athenex, Inc.
2MT
Exchange: DB
Founded: 2003
$659,146,076
67,023,498
Website: http://www.athenex.com
Address: Athenex, Inc.
1001 Main Street,
Suite 600,
Buffalo,
New York, 14203,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ATNX Common Stock Nasdaq Global Select US USD 14. Jun 2017
DB 2MT Common Stock Deutsche Boerse AG DE EUR 14. Jun 2017
Number of employees
Current staff
Staff numbers
579
Athenex employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 22:13
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/17
Last earnings filing: 2019/03/11
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.